Author Guidelines

Sections

1. Submission
2. Aims and Scope
3. Manuscript Categories and Requirements
    a. Randomised Clinical Trials 
4. Preparing Your Submission
5. Editorial Policies and Ethical Considerations
6. Author Licensing
7. Publication Process After Acceptance
8. Post Publication

1. SUBMISSION

Thank you for your interest in Alimentary Pharmacology & Therapeutics. Note that submission implies that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium, in which case, such should be clearly stated.

New submissions should be made via the Research Exchange submission portal https://wiley.atyponrex.com/journal/APT. You may check the status of your submission at any time by logging on to submission.wiley.com and clicking the “My Submissions” button. For technical help with the submission system, please review our FAQs or contact [email protected].

Free Format submission

Alimentary Pharmacology & Therapeutics now offers Free Format submission for a simplified and streamlined submission process.

Before you submit, you will need:

  • Your manuscript: this should be an editable file including text, figures, and tables, or separate files – whichever you prefer. All required sections should be contained in your manuscript, including abstract (which does need to be correctly styled), introduction, methods, results, and conclusions. Figures and tables should have legends. Figures should be uploaded in the highest resolution possible. If the figures are not of sufficiently high quality your manuscript may be delayed. References may be submitted in any style or format, as long as it is consistent throughout the manuscript. Supporting information should be submitted in separate files. If the manuscript, figures or tables are difficult for you to read, they will also be difficult for the editors and reviewers, and the editorial office will send it back to you for revision. Your manuscript may also be sent back to you for revision if the quality of English language is poor.
  • An ORCID ID, freely available at https://orcid.org. (Why is this important? Your article, if accepted and published, will be attached to your ORCID profile. Institutions and funders are increasingly requiring authors to have ORCID IDs.)
  • The title page of the manuscript, including:
    • Your co-author details, including affiliation and email address. (Why is this important? We need to keep all co-authors informed of the outcome of the peer review process.)
    • Statements relating to our ethics and integrity policies, which may include any of the following (Why are these important? We need to uphold rigorous ethical standards for the research we consider for publication):
      • data availability statement
      • funding statement
      • conflict of interest disclosure
      • ethics approval statement
      • patient consent statement
      • permission to reproduce material from other sources
      • clinical trial registration
You can use Wiley's 'Manuscript Language Checker' service at https://en.wileyeditingservices.com/english-language-checker-service-recommender. This is an entirely free service which allows authors to upload their manuscript and have it scanned for language, grammar, and flow. It will deliver a language quality score which suggests how ready the manuscript is for submission.

Once you have prepared your submission in accordance with the Guidelines, manuscripts should be submitted online at https://wiley.atyponrex.com/journal/APT.

For help with submissions, please contact: [email protected]

We look forward to your submission.

Data Protection and Privacy

By submitting a manuscript to, or reviewing for, this publication, your name, email address, institutional affiliation, and other contact details the publication might require, will be used for the regular operations of the publication, including, when necessary, sharing with the publisher (Wiley) and partners for production and publication. The publication and the publisher recognize the importance of protecting the personal information collected from users in the operation of these services, and have practices in place to ensure that steps are taken to maintain the security, integrity, and privacy of the personal data collected and processed. You can learn more at https://authorservices.wiley.com/statements/data-protection-policy.html.

2. AIMS AND SCOPE

Alimentary Pharmacology & Therapeutics (AP&T) is an international journal of gastroenterology and hepatology. The journal accepts original papers and systematic reviews concerned with clinical gastroenterology and hepatology. AP&T is particularly interested in therapies and diagnostics, including all aspects of translation from bench to bedside: identification of novel therapeutic targets, epidemiology, clinical trials, drug safety and meta-analyses. Descriptions of adverse effects (but not case reports) and pharmacoepidemiological and toxicological aspects will also be considered. AP&T only publishes studies performed in human subjects.

Preprint Policy

Alimentary Pharmacology & Therapeutics will consider for review articles previously available as preprints. Authors may also post the submitted version of a manuscript to a preprint server at any time. Authors are requested to update any pre-publication versions with a link to the final published article.

3. MANUSCRIPT CATEGORIES AND REQUIREMENTS

Alimentary Pharmacology & Therapeutics publishes a number of different article types including:

Original Articles
AP&T does not have an exact word count for any article, as all articles vary, but the introduction, methods, results, discussion and references should be approximately 12-20 pages of double-spaced A4 (with approximately 300 words per page – font size 12). Please insert the total word count (excluding summary) on the front page of your submitted article.
AP&T will consider all figures, tables and references which are relevant to the submitted manuscript but additional relevant text, tables, figures and references can also be submitted as Supporting Information – i.e. if the article is accepted for publication, you cite the Supporting Information within the text of the main article, and this can be viewed via a separate link at the end of the article.

Systematic Reviews
A systematic review is a review of published literature addressing a specific research question. It should include an exhaustive search of the literature to date. The search strategy used should be reported within the paper. The authors should define eligibility criteria for included studies a priori, and describe these. There should be evidence of independent judging of study eligibility, performed by at least two authors, with the degree of agreement between authors described. Data extraction from individual studies should also be performed in duplicate, and there should be evidence that any differences in data extraction were discussed between authors, and resolved.

The reporting of systematic reviews should adhere to the PRISMA statement – (for further information please see section below under ETHICS). Further guidance is also available from the Cochrane organisation’s “Reviewer’s Handbook”.

Reviews
A review article should still report the search strategy for the selection of relevant literature, but the approach may be less rigorous than described above, and the article might also reflect the personal experience and opinions of the Authors.

Consensus Guidelines
Consensus Guidelines will be considered providing that they tackle an area of clinical importance, have authorship that represents a national, or preferably international grouping, and that uses a systematic approach to achieve consensus eg Delphi. The article should otherwise follow the guidelines for a Review Article, including a structured summary which should include the key recommendations.

Meta-analyses

A meta-analysis is a statistical approach to combining data from individual studies identified in a systematic review that address a single research question. Although it is perfectly acceptable to perform a systematic review without a meta-analysis, a meta-analysis cannot be conducted without first performing a systematic review of the published literature.

Again, the reporting of meta-analyses should adhere to the PRISMA statement (for further information please see section below under ETHICS). Further guidance is also available from the Cochrane organisation’s “Reviewer’s Handbook”.

Clinical Trials

Please note: All randomised clinical trials must be registered with a clinical trials registry, or a statement provided in the paper to explain the omission.

‘Clinical trial' defined as 'any research study that prospectively assigns human participants or groups of humans to one or more health-related interventions to evaluate the effects on health outcomes'), please provide details of the registry and the registration number in the Methods section of your paper, close to your statement about Ethical issues, plus quoting the registration number at the end of the final line of the Conclusions in your Summary. Clinical trial reports should include the power of the study design and any deviations from the proposed protocol should be reported within the Methods section of the paper.

Letters to the Editor and Invited Editorials
Letters to the Editor and Invited Editorials are restricted to the discussion of papers already published in the journal (preferably within the last 18 – 24 months), WITH A MAXIMUM OF 500 WORDS, ONE TABLE OR FIGURE AND UP TO 10 REFERENCES.

SuperFast papers

We offer a separate fast appraisal and publication service for manuscripts. A submission fee of US$1,500 (plus VAT in the UK), guarantees full peer review within 6 working days, but it does not guarantee acceptance. Once a manuscript is accepted in its final form, it will be published as an EarlyView paper (edited, typeset and as corrected final proofs) within 20 to 28 days, and in a full issue of the journal about one month later; full details below. This service will not slow the standard prompt service provided by the journal.

Authors planning to submit a SuperFast paper are encouraged to contact the Editorial Office in advance of submission, so that peer-review can be planned in advance. An invoice will be issued by Wiley for the submission fee on submission of the manuscript via our “Superfast” process – please provide full details to whom this invoice should be sent (including an email address and/or fax number).

4. PREPARING YOUR SUBMISSION

Parts of the Manuscript

The manuscript should be submitted in separate files: main text file; figures.

Main Text File

The text file should be presented in the following order:

i. A short informative title containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips);
ii. The full names of the authors;
iii. The authors' institutional affiliations where the work was conducted (maximum of two affiliations per author), with a footnote for any author’s present address if different from where the work was conducted;
iv. Acknowledgments;
v. Structured summary (not exceeding 250 words) and keywords;
vi. Main text - Introduction, Materials and Methods, Results, and Discussion;
vii. References;
viii. Tables (each table complete with title and footnotes);
ix. Figure legends;
x. Appendices (if relevant).

Figures and supporting information should be supplied as separate files.

Title

The title should be a short, informative and containing the major key words. The title should not contain abbreviations (see Wiley's best practice SEO tips).

Please note: it is the journal style for AP&T to include a prefix in the title for some article types: 'Review article: ...', 'Systematic review: ...', 'Meta-analysis: ...', 'Clinical trial: ...'.

Authorship

Please refer to the journal’s Authorship policy in the Editorial Policies and Ethical Considerations section for details on author listing eligibility.

Acknowledgments

Contributions from anyone who does not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section. Financial and material support should also be mentioned. Thanks to anonymous reviewers are not appropriate.

Conflict of Interest Statement

Authors will be asked to provide a conflict of interest statement during the submission process. For details on what to include in this section, see the ‘Conflict of Interest’ section in the Editorial Policies and Ethical Considerations section below. Submitting authors should ensure they liaise with all co-authors to confirm agreement with the final statement.

Author Contributions

For all articles, the journal mandates the CRediT (Contribution Roles Taxonomy), for more information please see Author Services.

Summary

For all papers other than editorials or letters, ie including Review articles, please provide a structured summary of up to 250 words containing the major keywords summarizing the article. This should be a concise summary of the whole paper, not just the conclusions, and it must be understandable without reference to the rest of the paper. It should include the headings: Background/Aims/Methods/Results/Conclusions. It should contain no citation to any other published work. Abbreviations and acronyms should be avoided in the Summary.

Keywords

Please provide 3-7 keywords.

Main Text

• The journal uses British spelling.
AP&T does not have a strict total word count for articles (except for Letters and Editorials).

References

All references should be numbered consecutively in order of appearance. In text citations should cite references in consecutive order using Arabic superscript numerals.

For more information about this reference style, please see the AMA Manual of Style.

Reference examples follow:

Journal article

1. King VM, Armstrong DM, Apps R, Trott JR. Numerical aspects of pontine, lateral reticular, and inferior olivary projections to two paravermal cortical zones of the cat cerebellum. J Comp Neurol 1998;390:537-551.

Book

2. Voet D, Voet JG. Biochemistry. New York: John Wiley & Sons; 1990. 1223 p.

Please note that journal title abbreviations should conform to the practices of Chemical Abstracts.

Internet Document

1.

American Cancer Society. Cancer Facts & Figures 2003. http://www.cancer.org/downloads/STT/CAFF2003PWSecured.pdf. Accessed March 3, 2003.

Tables

Tables should be self-contained and complement, not duplicate, information contained in the text. They should be supplied as editable files, not pasted as images. Legends should be concise but comprehensive – the table, legend, and footnotes must be understandable without reference to the text. All abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings.

Figure Legends

Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement.

Figures

Although authors are encouraged to send the highest-quality figures possible, for peer-review purposes, a wide variety of formats, sizes, and resolutions are accepted. Click here for the basic figure requirements for figures submitted with manuscripts for initial peer review, as well as the more detailed post-acceptance figure requirements.

It is the policy of AP&T that all colour images are published at the journal's expense. All clinical and endoscopic pictures must be published in colour. For all other images, if colour enhances your submission and improves its readability, please supply the appropriate figure(s) in colour. Please choose colours carefully and use pastel shades to ensure a high standard of presentation. The editors reserve the right to add colour where it will improve the article.


Additional Files

Graphical Summary
Please include a graphical summary when submitting a revised version of your paper. See here for various example template options from which you may use one to prepare your graphical summary. Wiley Editing Services offers expert help with graphical summary design if desired.

Appendices

Appendices will be published after the references. For submission they should be supplied as separate files but referred to in the text.

Supporting Information

Supporting information is information that is not essential to the article, but provides greater depth and background. It is hosted online and appears without editing or typesetting. It may include tables, figures, videos, datasets, etc.

Click here for Wiley’s FAQs on supporting information.

Note: if data, scripts, or other artefacts used to generate the analyses presented in the paper are available via a publicly available data repository, authors should include a reference to the location of the material within their paper.

General Style Points

The following points provide general advice on formatting and style.

Abbreviations: The use of new, or rarely used, acronyms (an abbreviation formed from the initial letters of other words and pronounced as a word, for example GERD or NAFLD) or simple abbreviations much decrease the readability of any article. Please keep the number of acronyms or abbreviations used within your manuscript to an absolute minimum to ensure your article is easy to read and understand.
Dosing intervals: If possible spell out the intervals in full, such as twice a day, or three times a day. Otherwise use consistently either the European style of b.d., t.d.s. or q.d.s. etc., or the American style b.i.d., t.i.d., or q.i.d. etc.
Units of measurement: Measurements should be given in SI or SI-derived units. Visit the Bureau International des Poids et Mesures (BIPM) website for more information about SI units.
Numbers: numbers under 10 are spelled out, except for: measurements with a unit (8mmol/l); age (6 weeks old), or lists with other numbers (11 dogs, 9 cats, 4 gerbils).
Trade Names: Chemical substances should be referred to by the generic name only. Trade names should not be used. Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name and the name and location of the manufacturer in parentheses. Drug names are spelled out according to the European pharmacopoeia, but the American spelling should be used after the first use of a drug name.

Article Preparation Support

Wiley Editing Services offers expert help with English Language Editing, as well as translation, manuscript formatting, figure illustration, figure formatting, and graphical abstract design – so you can submit your manuscript with confidence.

Also, check out our resources for Preparing Your Article for general guidance about writing and preparing your manuscript.       

5. EDITORIAL POLICIES AND ETHICAL CONSIDERATIONS

Peer Review and Acceptance

The acceptance criteria for all papers are the quality and originality of the research and its significance to journal readership. The journal operates a single-blind peer-review process using a body of over 5,500 expert peer reviewers; papers are normally reviewed by two or more reviewers plus one or more Editors. Invited Editorials and Letters to the Editors about past papers in AP&T are not usually subject to peer review, but are always shared with the authors of the original paper prior to publication, with a right to reply. All substantive papers - original articles, reviews (commissioned and non-commissioned), meta-analyses and systematic reviews, and randomised clinical trials, including those published Open Access – undergo the same vigorous and consistent peer review process. Papers will only be sent out for peer-review if the Editors determine that the paper meets the appropriate quality and relevance requirements.

Wiley's policy on the confidentiality of the review process is available here.

Refer and Transfer Program 

Wiley believes that no valuable research should go unshared. This journal participates in Wiley’s Refer & Transfer program. If your manuscript is not accepted, you may receive a recommendation to transfer your manuscript to another suitable Wiley journal, either through a referral from the journal’s editor or through our Transfer Desk Assistant. 

Data Sharing and Data Accessibility

AP&T expects that data supporting the results in the paper will be archived in an appropriate public repository. Authors are required to provide a data availability statement to describe the availability or the absence of shared data. When data have been shared, authors are required to include in their data availability statement a link to the repository they have used, and to cite the data they have shared. Whenever possible the scripts and other artefacts used to generate the analyses presented in the paper should also be publicly archived. If sharing data compromises ethical standards or legal requirements then authors are not expected to share it.

Review Wiley’s Data Sharing policy where you will be able to see and select the data availability statement that is right for your submission.

Human Studies and Subjects

For manuscripts reporting medical studies that involve human participants, a statement identifying the ethics committee that approved the study and confirmation that the study conforms to recognized standards is required, for example: Declaration of Helsinki; US Federal Policy for the Protection of Human Subjects; or European Medicines Agency Guidelines for Good Clinical Practice. It should also state clearly in the text that all persons gave their informed consent prior to their inclusion in the study.

Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used). Images and information from individual participants will only be published where the authors have obtained the individual's free prior informed consent. Authors do not need to provide a copy of the consent form to the publisher; however, in signing the author license to publish, authors are required to confirm that consent has been obtained. Wiley has a standard patient consent form available for use.

Clinical Trial Registration

The journal requires that clinical trials are prospectively registered in a publicly accessible database and clinical trial registration numbers should be included in all papers that report their results. Authors are asked to include the name of the trial register and the clinical trial registration number at the end of the abstract. If the trial is not registered, or was registered retrospectively, the reasons for this should be explained.

Research Reporting Guidelines

Accurate and complete reporting enables readers to fully appraise research, replicate it, and use it. Authors are expected to adhere to recognised research reporting standards. The EQUATOR Network collects more than 370 reporting guidelines for many study types, including for:

Randomised trials: CONSORT
Observational studies: STROBE
Systematic reviews: PRISMA
Case reports: CARE
Qualitative research: SRQR
Diagnostic / prognostic studies: STARD
Quality improvement studies: SQUIRE
Economic evaluations: CHEERS
Study protocols: SPIRIT
Clinical practice guidelines: AGREE

We also encourage authors to refer to and follow guidelines from:

Future of Research Communications and e-Scholarship (FORCE11)
The Gold Standard Publication Checklist from Hooijmans and colleagues
Minimum Information Guidelines from Diverse Bioscience Communities (MIBBI) website
FAIRsharing website

Genetic Nomenclature

Sequence variants should be described in the text and tables using both DNA and protein designations whenever appropriate. Sequence variant nomenclature must follow the current HGVS guidelines; see http://varnomen.hgvs.org/, where examples of acceptable nomenclature are provided.

Sequence Data

Nucleotide sequence data can be submitted in electronic form to any of the three major collaborative databases: DDBJ, EMBL, or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL, and GenBank on a daily basis. The suggested wording for referring to accession-number information is: ‘These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345’. Addresses are as follows:

• DNA Data Bank of Japan (DDBJ): http://www.ddbj.nig.ac.jp


• EMBL Nucleotide Archive: ebi.ac.uk/ena
• GenBank: www.ncbi.nlm.nih.gov/genbank

Proteins sequence data should be submitted to either of the following repositories:

• Protein Information Resource (PIR): pir.georgetown.edu
• SWISS-PROT: expasy.ch/sprot/sprot-top

Funding and Conflict of Interest

The journal requires that all authors disclose any potential sources of conflict of interest and funding sources. Any interest or relationship, financial or otherwise that might be perceived as influencing an author's objectivity is considered a potential source of conflict of interest. These must be disclosed when directly relevant or directly related to the work that the authors describe in their manuscript.

Sources of financial support during the last two years must be acknowledged. Please read the following statements, adding those sections which are relevant at the end of your submitted manuscript under a heading 'Statement of Interests'.

1. Authors' declaration of personal interests:
i. [Name of individual] has served as a speaker, a consultant and an advisory board member for [names of organisations], and has received research funding from [names of organisation].
ii. [Name of individual] is an employee of [name of organisation].
iii. [Name of individual] owns stocks and shares in [name of organisation].
iv. [Name of individual] owns patent [patent identification and brief description].
2. Declaration of funding interests:
i. This study was funded [in part or in full] by [insert name of funding organisation], grant number [insert grant or other identification number].
ii. The [writing or preparation] of this paper was funded in part by [insert name of funding organisation].*
iii. Initial data analyses were undertaken by [name of individuals if not listed as authors] who are employees of [name company] and received funding from [insert name of funding organisation].
iv. Writing support was provided by [insert name of individual(s)] of [name company] and funded by [insert name of funding organisation].*

*See below, ‘Role of professional medical writers in peer-reviewed publications’.

The existence of a conflict of interest does not preclude publication. If the authors have no conflict of interest to declare, they must also state this at submission. It is the responsibility of the corresponding author to review this policy with all authors and collectively to disclose with the submission ALL pertinent commercial and other relationships. If in doubt, please check the Open Funder Registry for the correct nomenclature: https://www.crossref.org/services/funder-registry/.

Authorship

The list of authors (see point 5) should accurately illustrate who contributed to the work and how. All those listed as authors should qualify for authorship according to the following criteria:

1. Have made substantial contributions to conception and design, or acquisition of data, or analysis and interpretation of data;

2. Been involved in drafting the manuscript or revising it critically for important intellectual content;

3. Given final approval of the version to be published. Each author should have participated sufficiently in the work to take public responsibility for appropriate portions of the content; and

4. Agreed to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

5. If there are collaborators who, for example may have recruited patients to a study, but do not otherwise warrant inclusion as authors, these can be included in an Appendix at the end of the paper and a group name provided (for example, 'Swedish IBD Study Group') at the end of the author listing on the actual paper. This group name will then capture the list of all the collaborators on PubMed.

6. Contributions from others who do not meet the criteria for authorship should be listed, with permission from the contributor, in an Acknowledgments section (for example, to recognize contributions from people who provided technical help, collation of data, writing assistance, acquisition of funding, or a department chairperson who provided general support). Prior to submitting the article all authors should agree on the order in which their names will be listed in the manuscript.

7. A section entitled 'Authorship Statement' must be completed for every manuscript and must identify the following:

Guarantor of article: The name of the author who is acting as the submission's guarantor (i.e. the person who takes responsibility for the integrity of the work as a whole, from inception to published article).
Specific author contributions: An author may list more than one contribution, and more than one author may have contributed to the same element of the work (e.g. 'A performed the research, A and C collected and analysed the data, E designed the research study and wrote the paper, and G contributed to the design of the study).
A statement indicating that ALL authors approved the final version of the article, including the authorship list. (Please note: This information needs to be included both during the submission and also within the Acknowledgements of the submitted manuscript).

8. Additional Authorship Options. Joint first or senior authorship: In the case of joint first authorship, a footnote should be added to the author listing, e.g. ‘X and Y should be considered joint first author’ or ‘X and Y should be considered joint senior author.’

9. Role of professional medical writers in peer-reviewed publications

Please ensure that you follow the guidelines by the European Medical Writers Association on the role of medical writers. The guidelines emphasise the importance of respecting widely recognised authorship criteria, and in particular of ensuring that all people listed as named authors have full control of the content of papers. The role of professional medical writers must be transparent. Please name any professional medical writer among the list of authors in any article for Alimentary Pharmacology and Therapeutics (not only original research papers), and specify who paid the writer in the acknowledgements and statement of competing interests for the article. Writers and authors must have access to relevant data while writing papers. Medical writers have professional responsibilities to ensure that the papers they write are scientifically valid and are written in accordance with generally accepted ethical standards.

Publication Ethics

This journal is a member of the Committee on Publication Ethics (COPE). Note this journal uses iThenticate’s CrossCheck software to detect instances of overlapping and similar text in submitted manuscripts. Read Wiley'sTop 10 Publishing Ethics Tips for Authors here. Wiley’s Publication Ethics Guidelines can be found here.

Correction to Authorship

In accordance with Wiley’s Best Practice Guidelines on Research Integrity and Publishing Ethics and the Committee on Publication Ethics’ guidance, AP&T will allow authors to correct authorship on a submitted, accepted, or published article if a valid reason exists to do so. All authors – including those to be added or removed – must agree to any proposed change. To request a change to the author list, please complete the Request for Changes to a Journal Article Author List Form and contact either the journal’s editorial or production office, depending on the status of the article. Authorship changes will not be considered without a fully completed Author Change form. [Correcting the authorship is different from changing an author’s name; the relevant policy for that can be found in Wiley’s Best Practice Guidelines under “Author name changes after publication.”]



Author Name Change Policy

In cases where authors wish to change their name following publication, Wiley will update and republish the paper and redeliver the updated metadata to indexing services. Our editorial and production teams will use discretion in recognizing that name changes may be of a sensitive and private nature for various reasons including (but not limited to) alignment with gender identity, or as a result of marriage, divorce, or religious conversion. Accordingly, to protect the author’s privacy, we will not publish a correction notice to the paper, and we will not notify co-authors of the change. Authors should contact the journal’s Editorial Office with their name change request.

Artificial Intelligence Generated Content

Artificial Intelligence Generated Content (AIGC) tools—such as ChatGPT and others based on large language models (LLMs)—cannot be considered capable of initiating an original piece of research without direction by human authors. They also cannot be accountable for a published work or for research design, which is a generally held requirement of authorship (as discussed in the previous section), nor do they have legal standing or the ability to hold or assign copyright. Therefore—in accordance with COPE’s position statement on AI tools—these tools cannot fulfill the role of, nor be listed as, an author of an article. If an author has used this kind of tool to develop any portion of a manuscript, its use must be described, transparently and in detail, in the Methods or Acknowledgements section. The author is fully responsible for the accuracy of any information provided by the tool and for correctly referencing any supporting work on which that information depends. Tools that are used to improve spelling, grammar, and general editing are not included in the scope of these guidelines. The final decision about whether use of an AIGC tool is appropriate or permissible in the circumstances of a submitted manuscript or a published article lies with the journal’s editor or other party responsible for the publication’s editorial policy.




6. AUTHOR LICENSING

If a paper is accepted for publication, the author identified as the formal corresponding author will receive an email prompting them to log in to Author Services, where via the Wiley Author Licensing Service (WALS) they are required to complete a copyright license agreement on behalf of all authors of the paper.

General information regarding licensing and copyright is available here.

Self-Archiving definitions and policies. Note that the journal’s standard copyright agreement allows for self-archiving of different versions of the article under specific conditions. Please click here for more detailed information about self-archiving definitions and policies.

7. PUBLICATION PROCESS AFTER ACCEPTANCE

Accepted Articles

All accepted manuscripts are subject to editing. Authors have final approval of changes prior to publication.

Proofs

Once the paper is typeset, the author will receive an email notification with full instructions on how to provide proof corrections.

Please note that the author is responsible for all statements made in their work, including changes made during the editorial process – authors should check proofs carefully. Note that proofs should be returned within 48 hours from receipt.

Early View

All edited articles (except for Letters and Editorials) will appear 20-25 days after acceptance in the Alimentary Pharmacology & Therapeutics Early View section of the Wiley Online Library. Early View articles are complete full-text articles published online in advance of their publication in an online issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled issue. Early View articles are complete and final. They will have been fully reviewed, revised and edited for publication, and the authors’ final corrections, if any, will have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After publication, the DOI remains valid and can continue to be used to cite and access the article.

Open Access

Open Access is available to authors of primary research articles who wish to make their article available to non-subscribers on publication, or whose funding agency requires grantees to archive the final version of their article. With Open Access, the author, the author's funding agency, or the author's institution pays a fee (Article Publication Charge, or APC) to ensure that the article is made available to non-subscribers upon publication via Wiley Online Library, as well as deposited in the funding agency's preferred archive. 

For more information on this journal’s APCs, please see the Open Access page.

Prior to acceptance there is no requirement to inform an Editorial Office that you intend to publish your paper Open Access if you do not wish to. All Open Access articles are treated in the same way as any other article. They go through the journal's standard peer-review process and will be accepted or rejected based on their own merit.

Co-publication of Cochrane Reviews

AP&T encourages the submission of published Cochrane reviews and we are currently seeking a Co-Publication Agreement with The Cochrane Collaboration for such published reviews. Please visit "Publication of versions of Cochrane reviews in print journals" for guidelines for publishing in AP&T. Such submissions should not be a straight duplication of the original published Cochrane review and will usually be substantially shorter and focus on the more important clinical aspects of the review. They will also be subject to our usual peer review process and must cite the original publication.

Supplements

You can contact our Supplements team via the 'Contact' link on the left-hand side of your screen. Our team will be able to provide advice and quotations for supplements. Details on the preparation and submissions of supplement articles can be found here.

8. POST PUBLICATION

Access and Sharing

When the article is published online:

• The author receives an email alert (if requested).
• The link to the published article can be shared through social media.
• The author will have free access to the paper (after accepting the Terms & Conditions of use, they can view the article).
• The corresponding author and co-authors can nominate up to ten colleagues to receive a publication alert and free online access to the article.

Article Promotion Support

Wiley Editing Services offers professional video, design, and writing services to create shareable video abstracts, infographics, conference posters, lay summaries, and research news stories for your research – so you can help your research get the attention it deserves.

Cover Image Submissions  

This journal accepts artwork submissions for Cover Images. This is an optional service you can use to help increase article exposure and showcase your research. For more information, including artwork guidelines, pricing, and submission details, please visit the Journal Cover Image page 

Measuring the Impact of an Article

Wiley also helps authors measure the impact of their research through specialist partnerships with Kudos and Altmetric.

SERIOUS RESEARCH MISCONDUCT

Very rarely, the Editors may have cause to suspect serious research misconduct, based on comments received or his/her own review of a paper. In this case, the article in question will be held in abeyance until this matter is resolved. The Editors will contact authors and any appropriate third party to ascertain whether the grounds for investigation are justified. If serious research misconduct is discovered, the Editors will contact the authors’ institutions after rejecting the paper.

Despite vigorous peer-review, it is possible that a paper that is fraudulent in some manner may be published. If this is discovered, it will immediately be retracted and appropriate steps will be taken to notify readers of the journal, and the authors’ institution. Retractions will include the word ‘Retraction’ in the title, so that they are identified as such on indexing systems, for example, PubMed.

In any case of serious research misconduct, all authors of such an article may be banned from future publication in Alimentary Pharmacology and Therapeutics.

Plagiarism and falsification

The Journal may scrutinise all papers for evidence of plagiarism and falsified data using specialised software. Plagiarism can comprise the following:

• multiple submission (i.e. to several journals at the same time);
• redundant publication (i.e. when the same data are published repeatedly, especially when articles contain an unacceptable degree of overlap but some original data, or in the case of the first time data are published (followed by subsequent redundant publications);
• self-plagiarism;
• reviewer misconduct (e.g. a reviewer making use of material obtained during review);
• changes to authorship after publication due to discovery of guest or ghost authors;
• deliberate omission of funding or competing interest information.

PUBLICATION OF CORRECTIONS

The Journal has a duty to publish corrections when errors could affect the interpretation of data or information, whatever the cause of the error (i.e. arising from author or publisher errors). It is important to set the scientific record straight. The term ‘Corrigendum’ will be used when the error is made by the author and ‘Erratum’ will be used when the error is made by the Publisher.

The title of the Corrigendum/Erratum will include the words 'Erratum' or 'Corrigendum'. They are published on a numbered page (print and electronic) and are listed in the Journal's table of contents. They will cite the original article and be linked to it, so that indexing and abstracting services are able to identify and link to both the erratum and the original paper.

APPEALS

Decisions on manuscripts or on ethical misconduct are regarded as final; however, we recognise the right of an individual to challenge our decisions and seek an appeal. For appeals on manuscripts or on ethical grounds, please contact Professor Roy Pounder, Professor Colin Howden or Professor Rohit Loomba in the first instance, who will be given full access to the submitted materials and all correspondence. They will conduct an inquiry independent of the original peer-review process. If an author is not satisfied with the decision from an appeal, two senior Reviewers will review the case independently and render a final binding decision.

HANDLING EDITORS’ CONFLICTS OF INTEREST AND PUBLICATIONS BY THE EDITORS OR EDITORIAL BOARD

Editors or Editorial Board members are never involved in editorial decisions about their own work.

Journal editors, Editorial Board members and other editorial staff (including peer reviewers) withdraw from discussions about submissions where any circumstances might prevent him/her offering unbiased editorial decisions.

When making editorial decisions about peer reviewed articles where an editor is an author or is acknowledged as a contributor, affected editors or staff members exclude themselves and are not involved in the publication decision. When editors are presented with papers where their own interests may impair their ability to make an unbiased editorial decision, he/she deputises decisions about the paper to a suitably qualified individual.

Editors disclose their competing interests twice yearly.

Author Guidelines updated 11th Julyf 2023